Clinical trial
Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of…
NCT00415168 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00415168 |
|---|---|
| Title | Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer |
| Official title | Phase 2 Study of ALIMTA® (Pemetrexed) Plus Cisplatin as First-Line Treatment of Gastric Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, cisplatin |
| Enrollment | 53 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Dec 22, 2006 |
| Last update posted | Aug 17, 2010 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: